Radiomics and Artificial Intelligence in Breast Cancer Imaging: Future Directions and Clinical Applicability

Breast cancer (BC): A global health burden

BC is the most frequently diagnosed cancer among women worldwide, surpassing lung cancer incidence, and remains the leading cause of cancer mortality among females. According to the Global Cancer Observatory (GLOBOCAN) 2020 data, BC accounts for approximately 2.3 million new cases and 685,000 deaths annually. Despite advancements in treatment, the prognosis of BC largely depends on the stage of diagnosis, emphasising the critical importance of early detection.^[1-4]

In developing countries, late-stage presentations are common because of limited access to screening programmes, a lack of awareness, and socioeconomic barriers. Even in developed nations with well-established screening initiatives, a significant number of cancers remain undetected or mischaracterised, owing to the intrinsic limitations of conventional imaging modalities.

Evolution of imaging in BC

Medical imaging is an indispensable tool for BC screening, diagnosis, staging, treatment planning, and monitoring. Traditional imaging modalities, including

• Mammography (cornerstone of screening).

• Ultrasound (especially in dense breasts)

• Magnetic Resonance Imaging (MRI) (high-sensitivity for high-risk women)

• Positron Emission Tomography (PET) (for metastatic disease) [Table 1].

They have significantly improved diagnostic outcomes.

However, these techniques rely heavily on human interpretation, introducing variability that is influenced by reader expertise, subjective judgement, and imaging quality.

Moreover, conventional imaging typically provides limited insight into tumour biology. Radiologists primarily assess morphological features, such as mass shape, margins, and density, which can sometimes mislead or obscure the aggressive nature of the disease.^[5-7]

Need for advanced imaging analytics

The current clinical workflow lacks a standardised mechanism for quantifying subtle and complex imaging phenotypes that are often associated with distinct tumour subtypes, genetic mutations, or treatment responses. This gap creates a critical need for methodologies that can be

• Extract vast amounts of quantitative information from images.

• Identify patterns imperceptible to the human eye.

• Predicts clinical outcomes with higher accuracy and reproducibility

• Support objective and personalised clinical decision-making.

Emerging disciplines, such as radiomics and artificial intelligence (AI), offer transformative solutions to these unmet needs, pushing the frontier from visual interpretation to data-driven precision diagnostics.

Emergence of radiomics and AI

Radiomics involves high-throughput extraction of large amounts of quantitative features from medical images. These features describe tumour characteristics, such as shape, texture, intensity, and spatial relationships, and can be linked to histopathology, genomics, or clinical outcomes.

AI, particularly Machine Learning (ML) and Deep Learning (DL), facilitates the analysis of complex datasets to uncover patterns, build predictive models, and automate diagnostic processes.

Together, radiomics and AI aim to create robust, noninvasive imaging biomarkers that enhance the current capabilities of radiologists and oncologists, ultimately improving patient outcomes.

Objectives of this manuscript

• This manuscript aims to provide a comprehensive overview of:

• Fundamental principles of radiomics and AI for BC imaging.

• Current applications and clinical evidence supporting their use.

• Challenges faced in the implementation and deployment

• Future directions, including radiogenomics, explainable AI (XAI), and integration into the clinical workflow

• Practical considerations for translating research innovations into real-world clinical practice.

Through an in-depth review of existing literature, case studies, and future perspectives, this study intends to guide radiologists, oncologists, researchers, and policymakers in harnessing these technologies to advance BC management.

Introduction

Imaging plays a pivotal role in early detection, diagnosis, treatment planning, and monitoring of BC. The efficacy of BC management relies heavily on the strengths and limitations of the imaging technologies. A comprehensive understanding of these modalities provides a critical foundation for the evaluation of the value of radiomics and AI in clinical practice.

Mammography

Breast ultrasound

MRI

Emerging modalities

Limitations of conventional imaging

Despite technological advances, conventional imaging modalities are still fraught with challenges:

• Inter-reader variability: interpretation of differences among radiologists.

• Limited predictive capacity: Cannot reliably predict tumour aggressiveness.

• False negatives and positives: potential for delayed diagnosis or unnecessary biopsies.

• Subjectivity: Dependent on the radiologist’s expertise and experience.

These limitations have set the stage for the integration of advanced analytical methods such as radiomics and AI into BC imaging.

Conclusion

Although traditional imaging methods have significantly contributed to progress in BC care, they leave room for improvement, particularly in predictive and personalised diagnostics. The emerging fields of radiomics and AI promise to address these gaps by extracting deeper, objective, and reproducible insights from imaging data to guide clinical decision-making more effectively.

Introduction

Radiomics is an emerging field that is at the intersection of medical imaging and data science. This refers to high-throughput extraction of a large number of quantitative features from radiological images, which enables the transformation of images into mineable data. These extracted features, which are not visible to the naked eye, can capture complex information regarding tissue heterogeneity, tumour biology, and disease processes. Radiomics aims to augment clinical decision-making by creating imaging biomarkers that can predict diagnosis, prognosis, and treatment response.

Definition and concept

Radiomics can be broadly defined as:

‘The process of converting standard medical images into large amounts of quantitative data through algorithmic analysis is subsequently used for decision support in diagnosis, treatment planning, and prognosis.’

Radiomics treats medical images as rich datasets rather than merely visual information, thus unlocking hidden patterns that correlate with clinical outcomes.

Radiomics workflow

The typical radiomics process involves several systematic steps [Figure 1]:

Close

Figure 1: Radiomics workflow.

Export to PPT

1. Image acquisition

   • Standardised imaging protocols are crucial for reproducibility.

2. Image segmentation

   • Manual, semi-automatic, or fully automated methods are used to define regions of interest, usually focusing on tumours or suspicious areas.

3. Feature extraction

   • Hundreds to thousands of features are extracted and categorised as follows:

     • Shape features (e.g., volume and surface area)

     • Intensity features (e.g., mean pixel values)

     • Textural features (e.g., heterogeneity and entropy)

     • Wavelet features (multiscale decomposition)

4. Feature selection

   • Redundant or noninformative features were filtered to avoid overfitting in the predictive models.

5. Model building

   • ML algorithms were trained to associate selected features with clinical endpoints (diagnosis, recurrence, and survival).

6. Validation and testing

   • Internal and external validation ensured the generalisability and reliability of the models.

Radiomics workflow diagram

Below is a simplified radiomics workflow diagram:

Clinical relevance of radiomics

Radiomics provides insights into:

• Tumour heterogeneity: Variation within tumours correlates with aggressiveness and prognosis.

• Non-invasive biomarkers: Radiomics eliminates the need for repeated biopsies.

• Risk stratification: early identification of high-risk patients for aggressive treatment.

• Therapy monitoring: Assesses responses to chemotherapy, targeted therapy, or radiation.

Radiomics offers a bridge between imaging phenotypes and personalised medicine, potentially altering the clinical pathway towards more customised therapeutic strategies.

Challenges in radiomics

While promising, radiomics faces critical challenges:

• Lack of imaging standardisation across centres

• Variability in segmentation methods

• Need for large annotated datasets for model training.

• Regulatory concerns regarding clinical validation and reproducibility.

• Interpretability and explainability of models

Addressing these challenges is essential for the transition of radiomics from the research domain to routine clinical practice.

Conclusion

Radiomics has the potential to revolutionise BC imaging by shifting the paradigm from subjective interpretation to data-driven decision-making. By harnessing the power of advanced computational analysis, radiomics can extract meaningful, reproducible, and quantifiable information from standard imaging modalities. The next step in this evolution involves the integration of radiomics with AI, which exponentially amplifies diagnostic and prognostic capabilities.

Introduction

AI refers to the simulation of human Intelligence, processes using machines, particularly computer systems. In medical imaging, AI systems aim to assist or even outperform humans in terms of image interpretation, diagnosis, and prediction. The advent of AI has opened new frontiers in BC imaging by enhancing the detection of subtle abnormalities, reducing observer variability, and enabling personalised treatment strategies.

AI, when combined with radiomics, provides a synergistic opportunity to extract, analyse, and interpret complex imaging data in ways that were previously impossible.

Evolution of AI in imaging

The development of AI in medical imaging has evolved through three primary stages:

• Rule-based systems: Early attempts used ‘if-then’ logic without learning capabilities.

• ML: Introduced algorithms that learn patterns from data.

• DL: A subset of ML that utilises neural networks with multiple layers for feature learning and pattern recognition.

Each progression has enhanced the ability of systems to autonomously improve their performance and tackle increasingly complex diagnostic challenges.

ML in medical imaging

Definition

ML involves teaching algorithms to recognise patterns in data and make decisions based on input features without explicit programming.

DL in medical imaging

AI Workflow in Imaging

Here’s the typical AI workflow in medical imaging [Figure 2]:

Close

Figure 2: AI workflow for BC imaging.

Export to PPT

Advantages of AI in BC imaging

• Increased sensitivity and specificity: AI can detect subtle lesions overlooked by radiologists.

• Reduction of human error: Minimises observer variability and fatigue-related mistakes.

• Real-time decision support: Provides on-the-spot recommendations during the clinical workflow.

• Quantitative output: Supplies objective risk scores instead of subjective impressions.

• Scalability: Once trained, AI models rapidly analyse thousands of images.

Limitations and challenges

Despite its potential, AI in breast imaging faces several hurdles:

• Data requirements: Require large annotated datasets for effective training.

• Generalisability: Models trained on specific populations may not perform well across demographics.

• Interpretability: Many deep-learning models function as ‘black boxes’ with unclear decision-making processes.

• Regulatory approval: Stringent validation and approval processes are required for clinical deployment.

• Ethical concerns: Biases in training data can lead to inequitable healthcare delivery.

The future of AI in medical imaging

Future advancements are likely to focus on:

• XAI: Creating AI decision processes is transparent and understandable.

• Federated learning: Collaborative model training without sharing patient data across institutions.

• Integration with multi-omics data: Combining imaging, genomic, and clinical data for comprehensive patient profiling.

• Real-world validation: Large-scale prospective trials demonstrating clinical benefits.

Conclusion

AI is revolutionising BC imaging by enabling the extraction and interpretation of complex data patterns far beyond human capabilities. When combined with radiomics, AI systems provide unprecedented opportunities for early detection, precise diagnosis, and personalised treatment strategies. However, realising the full clinical potential of AI poses significant technical, regulatory, and ethical challenges.

Introduction

Radiomics has become a critical area of research in BC imaging, offering the potential to decode tumour heterogeneity, predict biological behaviour, and assist in personalised treatment planning. By extracting large volumes of quantitative features from standard breast imaging modalities, radiomics enables the noninvasive assessment of tumour characteristics, surpassing the limitations of conventional radiologic evaluation.

Applications of radiomics in BC

Radiomics has been successfully applied to a wide range of clinical objectives:

Key studies demonstrating radiomics in BC

Several studies have showcased the value of radiomics:

• Study 1: The MRI-based radiomics model differentiated luminal from non-luminal tumours with an Area Under the Curve (AUC) > 0.85.

• Study 2: PET-CT-derived radiomic features predicted axillary lymph node metastasis with 82% accuracy.

• Study 3: Mammography-based radiomics signature predicted the recurrence risk in patients with early-stage BC.

Challenges in clinical translation

Despite encouraging results, challenges remain:

• Standardisation: Variability in acquisition protocols affects feature reproducibility.

• Data sharing: Requires large, multi-centre datasets for validation.

• Clinical validation: Radiomics models require prospective trials for real-world adoption.

• Integration with the clinical workflow: Seamless incorporation into existing radiology systems is necessary for practicality.

Conclusion

Radiomics represents a paradigm shift in BC imaging, moving focus from subjective visual assessments to objective quantitative analyses. Radiomics offers an unprecedented opportunity to improve the diagnostic accuracy, predict patient outcomes, and guide personalised treatment by revealing patterns that are invisible to the human eye. The future integration of AI and multi-omics data holds immense promise for realising the full potential of radiomics in clinical breast oncology.

Introduction

AI has revolutionised BC care across the entire clinical continuum, from screening and diagnosis to risk stratification and treatment planning. By leveraging DL algorithms and ML models, AI provides tools that surpass human capabilities in terms of pattern recognition, speed, and consistency.

In breast imaging, AI aims to enhance radiologist performance, reduce false negatives and positives, and facilitate early, precise, and personalised intervention strategies.

AI for BC detection

Detection remains the foundation for BC control. AI systems, particularly CNNs, have demonstrated impressive capabilities in identifying abnormalities in breast imaging modalities, such as mammography, ultrasound, and MRI [Table 3].

AI for BC diagnosis

Once a suspicious lesion is detected, AI assists in:

• Characterising lesions: Benign vs. Malignant

• Differentiating subtypes: Based on imaging phenotypes correlated with histopathology.

• Reducing unnecessary biopsies: By providing high-confidence benignity predictions.

Example:

• AI models achieved a diagnostic accuracy comparable to that of senior radiologists.

• Some DL algorithms report an AUC > 0.90 for BC diagnosis in large screening datasets.

AI for BC prognosis prediction

AI extends beyond detection and diagnosis by predicting:

• Tumour aggressiveness based on imaging phenotypes.

• Risk of recurrence: Leveraging radiomics and ML models

• Response to therapy: AI predicts pCR to neoadjuvant chemotherapy with high sensitivity.

Such predictive analytics empower clinicians to tailor treatment strategies early in the clinical course.

Comparative performance of AI vs. human readers

• Several studies have directly compared AI models with those of human radiologists.

Advantages of AI in clinical practice

• Enhanced efficiency: Faster reading times without sacrificing accuracy.

• Second-reader systems: AI acts as a second opinion to reduce diagnostic errors.

• Workload reduction: Alleviates the radiologist burden, especially in high-volume settings.

• Personalised risk prediction: Enables tailored follow-up and treatment.

Challenges of AI implementation

Despite promising results, clinical adoption faces challenges:

• Generalisation across populations: Models trained on specific demographics may not perform equally across diverse ethnicities or imaging equipment.

• Integration into workflow: Seamless incorporation into Picture Archiving and Communication Systems (PACS) is required.

• Interpretability: Black-box models limit clinician trust.

• Regulatory hurdles: Approval processes are stringent to ensure patient safety.

Future perspectives

The future of AI in BC imaging lies in:

• XAI: Transparent models for building trust among clinicians.

• Federated learning models: Cross-institution collaboration without data sharing.

• Multimodal integration: Combining mammography, MRI, ultrasound, genomics, and clinical data for holistic prediction.

Conclusion

AI holds the promise of transforming BC imaging by improving diagnostic accuracy, speeding up clinical workflows, and enabling earlier and more personalised interventions. However, overcoming the challenges related to trust, validation, and integration is essential before AI becomes a universally accepted part of routine clinical practice.

Introduction

Radiogenomics is an innovative interdisciplinary field that combines radiomics, the extraction of quantitative features from medical images, and the study of genes and their functions. The objective of radiogenomics is to identify the relationships between imaging phenotypes and the molecular and genetic profiles of tumours.

In BC, radiogenomics has emerged as a promising avenue for noninvasive tumour characterisation, personalised therapy prediction, and prognostic evaluation, without the need for invasive biopsies or repeated tissue sampling.

Concept of radiogenomics

Radiogenomics operates under the hypothesis that:

• Imaging phenotypes reflect the underlying genetic and molecular characteristics of tumours.

This relationship allows imaging to serve as a ‘virtual biopsy’, offering comprehensive insights into tumour biology in a completely noninvasive manner.

How radiogenomics works

Workflow:

1. Imaging feature extraction (Radiomics):

   • Quantitative features were extracted from modalities, such as MRI, mammography, and PET/CT.

2. Genomic profiling:

   • Tumour tissues were subjected to molecular testing (e.g., gene expression profiling and next-generation sequencing).

3. Association studies:

   • Statistical or ML methods establish correlations between imaging features and specific genomic signatures.

4. Predictive modelling:

   • Models have been developed to predict molecular subtypes, gene mutations, and therapeutic responses, based solely on imaging data.

Applications of radiogenomics in BC

Detection of specific gene mutations

Radiogenomics can predict the presence of key mutations such as:

• BRCA1/BRCA2 mutations

• PIK3CA mutations

• TP53 mutations

Clinical relevance: Patients with BRCA mutations may benefit from targeted therapies, such as PARP inhibitors, making early, non-invasive detection extremely valuable.

Advantages of radiogenomics

• Noninvasiveness: Reduces the need for multiple biopsies.

• Spatial and temporal assessment: Captures the entire tumour heterogeneity, unlike localised biopsies.

• Personalised oncology: Facilitates tailored treatment plans based on tumour biology.

• Dynamic monitoring: Allows tracking of tumour evolution over time through repeated imaging rather than invasive procedures.

Challenges in radiogenomics

• Standardisation issues: Variability in imaging protocols and genomic testing methods.

• Data complexity: Integration of high-dimensional imaging and genomic data requires sophisticated computational methods.

• Limited datasets: Need for large, multi-institutional datasets with linked imaging and genomic data.

• Interpretability: Understanding the biological basis of imaging-genomic correlations remains a challenge.

Recent studies and progress

Several studies have advanced radiogenomics in BC:

• Study 1:

Found MRI texture features predictive of HER2 amplification status.^[3]

• Study 2:

Demonstrated correlations between dynamic contrast-enhanced MRI features and gene expression profiles related to angiogenesis and hypoxia.^[4]

• Study 3:

Developed machine-learning models linking mammographic radiomic features to Oncotype DX recurrence scores.

Future directions

The future of radiogenomics lies in:

• Multi-Omics Integration

Combining radiomic, genomic, proteomic, and metabolomic data for a holistic tumour profile.

• Explainable models: Enhancing interpretability to promote clinical adoption.

• Prospective trials: Large-scale validation studies to establish clinical utility.

• Personalised predictive oncology: Tailoring preventive, diagnostic, and therapeutic strategies at the individual patient level based on imaging genomic biomarkers.

Conclusion

Radiogenomics represents a powerful frontier in precision oncology, offering the promise of personalised BC management using noninvasive imaging biomarkers. By linking imaging phenotypes to tumour genomics, radiogenomics not only improves diagnostic and prognostic capabilities but also paves the way for individualised therapy selection. Continuous research, validation, and technological advancements are critical for the translation from research to clinical practice.

Introduction

Despite significant advances and promising early results, the clinical translation of radiomics and AI in BC imaging faces substantial challenges. These barriers span the technical, clinical, regulatory, and ethical domains, necessitating systematic solutions before these technologies can be fully integrated into routine patient care.

Technical challenges

Clinical challenges

Regulatory approval

AI models must undergo rigorous evaluation for safety, efficacy, and fairness before regulatory bodies, such as the FDA or CE, grant clinical approval.

Data privacy and security

The use of imaging data, especially in multicentre studies, raises concerns regarding patient confidentiality and compliance with regulations, such as HIPAA and GDPR.

Bias and fairness

AI models trained on non-diverse datasets may exhibit biases based on ethnicity, age, or socioeconomic status, potentially perpetuating healthcare inequalities.

Current initiatives addressing challenges

Image Biomarker Standardisation Initiative (IBSI): Working towards standardised methods for radiomics feature extraction and analysis.

Federated learning models: Enable AI training across multiple centres without sharing sensitive patient data.

XAI research: Focusing on making AI models’ decision-making processes more transparent and understandable for clinicians.

AI regulatory framework: Emerging standards from the FDA, EU MDR (Medical Device Regulation), and International Medical Device Regulators Forum (IMDRF) for approving AI medical devices.

Conclusion

Radiomics and AI offer tremendous opportunities for enhancing BC imaging and care. However, their clinical adoption hinges on overcoming significant challenges related to standardisation, reproducibility, clinical validation, ethical considerations, and regulatory approval. Multidisciplinary collaboration among radiologists, oncologists, computer scientists, ethicists, and regulators is essential to ensure that these powerful tools are developed responsibly and implemented safely for patient benefits.

Multi-omics integration

Future diagnostic models will no longer rely solely on imaging or genomics but will integrate multiple layers of biological data [Figure 3].

Close

Figure 3: Future integrated diagnostic model.

Export to PPT

• Genomics: DNA mutations and gene expression profiles

• Transcriptomic analysis: RNA sequencing.

• Proteomics: Protein expression and interaction profiles

• Metabolomics: Cellular metabolic pathways

• Radiomics: Imaging-derived quantitative features.

Clinical relevance: This holistic approach will enable comprehensive tumour profiling and offer unprecedented insights into cancer biology and therapeutic customisation.

Real-time clinical decision support systems

Future breast imaging workflows will integrate AI-driven decision support at the point-of-care.

Real-time analysis of imaging data will allow:

• Immediate identification of suspicious findings.

• Instant risk scoring

• Automated recommendations for follow-up, biopsy, or treatment.

This will significantly enhance diagnostic efficiency and standardise patient management.

Federated learning and data privacy

Sharing patient imaging and genomic data across institutions is challenging owing to privacy concerns. Federated learning offers a solution by allowing AI models to be trained across decentralised datasets, without transferring sensitive patient information.

Advantages:

• Preservation of patient confidentiality.

• Promotes collaboration across institutions

• Enables building robust generalised AI models

Predictive and preventive oncology

With the integration of AI and radiomics, BC care will shift from a reactive to a proactive model.

• Predictive analytics: Identify high-risk patients before disease onset.

• Preventive strategies: Tailor screening and risk-reduction interventions based on individualised risk profiles.

Personalised imaging biomarkers

Instead of using one-size-fits-all biomarkers, future radiomics models will generate patient-specific imaging biomarkers that dynamically evolve based on disease progression, treatment responses, and molecular alterations.

Evolution of AI algorithms

Future AI systems will feature:

• Continuous learning: AI models that adapt and improve with new data.

• Hybrid models: Combining human expertise with AI predictions for optimal outcomes.

• Adaptive diagnostics: Real-time adjustment of imaging protocols based on preliminary AI analysis during scans.

Challenges in future implementation

While the future appears promising, several hurdles must be addressed:

• Data standardisation across imaging centres

• Interoperability between different AI systems and hospital IT infrastructure.

• Ethical use of predictive algorithms.

• Ongoing regulatory oversight

• Continued human oversight to ensure patient safety.

Conclusion

The future of radiomics and AI in BC imaging lies in comprehensive data integration, transparency, personalisation, and global collaboration. Emerging technologies, such as multi-omics analytics, XAI, federated learning, and real-time decision support systems, will redefine cancer diagnosis and management. By embracing these innovations, the medical community has moved closer to delivering precision oncology, offering the right intervention to patients at the right time.

Introduction

Translation of radiomics and AI from research laboratories into everyday clinical practice is the ultimate goal. However, the journey from promising experimental results to real-world utility involves addressing practical, logistical, economic and ethical challenges. This chapter explores the clinical applicability of radiomics and AI in BC imaging, and evaluates their transformative potential and implementation limitations.

Integration into clinical workflow

The seamless incorporation of AI and radiomics into existing hospital infrastructure is critical for success. Clinical workflow integration requires the following steps:

• Interfacing with PACS: AI systems should easily retrieve, analyse, and return results to the PACS.

• User-friendly interfaces: Outputs must be intuitive, highlighting risk scores, feature maps, and diagnostic probabilities.

• Minimal disruption: Radiologists should view AI as an aid, not an obstacle, and maintain their autonomy in final decision making.

• Training and education: Radiologists, oncologists, and technologists must be trained to interpret and trust AI outputs appropriately.

Areas of clinical utility

Radiomics and AI can serve multiple roles in BC imaging:

• Screening support: Identifying suspicious lesions on mammograms, particularly in dense breasts.

• Triage: Prioritizing high-risk cases for urgent review.

• Second opinion: Acting as a double reader to reduce diagnostic errors.

• Risk stratification: Tailoring follow-up intervals and imaging modalities based on individualised risk.

• Predictive analytics: Estimating response to therapy and prognosis.

Cost-benefit analysis

Patient acceptability

Patient perspectives are crucial in the adoption of AI-based healthcare technologies.

Key findings from studies:

• Trust in human oversight: Patients prefer AI as a support tool, not as the sole decision-maker.

• Transparency: Willingness to accept AI increases if patients are informed of how AI decisions are made.

• Accuracy: Patients showed a strong preference for technologies that offered a demonstrably higher diagnostic accuracy.

Patient education about the role and benefits of AI is essential to foster acceptance.

Regulatory approvals and clinical validation

Before clinical deployment, radiomics and AI tools must receive regulatory approvals ensuring:

• Safety: Models must not introduce harm.

• Efficacy: Models must demonstrate the benefits of standard care.

• Equity: Models must function across diverse populations without introducing bias.

Clinical validation requires prospective trials in real-world settings, not just retrospective performance studies.

AI adoption curve in BC imaging

Curve description:

• Innovators (early adopters): Top academic centres and research hospitals.

• Early majority: Large private hospitals and cancer centres.

• Late majority: Community hospitals

• Laggards: Small clinics and low-resource settings.

(graphically, a bell-shaped or sigmoid (S-shaped) curve).

Case studies demonstrating clinical utility

Case study 1: Massachusetts General Hospital implemented an AI system for mammogram triage, reducing the radiologist’s reading time by 30% without sacrificing the diagnostic accuracy.

Case study 2: Google Health AI showed better sensitivity and specificity for BC screening than human readers across large screening cohorts.

These real-world examples showcase the tangible benefits achievable when AI is properly integrated into clinical practice.